International comparison of trends in patients commencing renal replacement therapy by primary renal disease

Stel VS 1 , Awadhpersad R 1 , Pippias M 1 , Ferrer-Alamar M 2 , Finne P 3 , Fraser SD 4 Show all authors , Heaf JG 5 , Hemmelder MH 6 , Martínez-Castelao A 7 , de Meester J 8 , Palsson R 9 , Prischl FC 10 , Segelmark M 11 , Traynor JP 12 , Santamaria R 13 , Reisaeter AV 14 , Massy ZA 15 , Jager KJ 1

Affiliations 

  • 1 ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
  • 2 Renal Registry Valencian Region, Generalitat Valencian, Spain
  • 3 Department of Nephrology, Helsinki University Hospital, Helsinki, Finland
  • 4 Academic Unit of Primary Care and Population Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK
  • 5 Department of Medicine, Zealand University Hospital, Roskilde, Denmark
  • 6 Dutch Renal Registry Renine, Nefrovisie Foundation, Utrecht, the Netherlands
  • 7 Nephrology Department, Bellvitge's University Hospital, Hospitalet, Barcelona, Spain
  • 8 Department of Nephrology & Dialysis & Hypertension, Dutch-speaking Belgian Renal Registry (NBVN), Sint-Niklaas, Belgium
  • 9 Division of Nephrology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland
  • 10 Department of Nephrology, Fourth Department of Internal Medicine, Klinikum Wels-Grieskirchen, Wels, Austria
  • 11 Department of Clinical Sciences Lund, Nephrology, Lund University, Skane University Hospital, Lund, Sweden
  • 12 Scottish Renal Registry, ISD Scotland, Glasgow, UK
  • 13 Nephrology Service, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain
  • 14 Norwegian Renal Registry, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway
  • 15 Division of Nephrology, Ambroise Pare University Hospital, APHP, University of Paris Ouest-Versailles-St-Quentin-en-Yvelines (UVSQ), Paris, France
Nephrology (Carlton), 2019 Oct;24(10):1064-1076.
PMID: 30456883 DOI: 10.1111/nep.13531

Abstract

AIM: To examine international time trends in the incidence of renal replacement therapy (RRT) for end-stage renal disease (ESRD) by primary renal disease (PRD).

METHODS: Renal registries reporting on patients starting RRT per million population for ESRD by PRD from 2005 to 2014, were identified by internet search and literature review. The average annual percentage change (AAPC) with a 95% confidence interval (CI) of the time trends was computed using Joinpoint regression.

RESULTS: There was a significant decrease in the incidence of RRT for ESRD due to diabetes mellitus (DM) in Europe (AAPC = -0.9; 95%CI -1.3; -0.5) and to hypertension/renal vascular disease (HT/RVD) in Australia (AAPC = -1.8; 95%CI -3.3; -0.3), Canada (AAPC = -2.9; 95%CI -4.4; -1.5) and Europe (AAPC = -1.1; 95%CI -2.1; -0.0). A decrease or stabilization was observed for glomerulonephritis in all regions and for autosomal dominant polycystic kidney disease (ADPKD) in all regions except for Malaysia and the Republic of Korea. An increase of 5.2-16.3% was observed for DM, HT/RVD and ADPKD in Malaysia and the Republic of Korea.

CONCLUSION: Large international differences exist in the trends in incidence of RRT by primary renal disease. Mapping of these international trends is the first step in defining the causes and successful preventative measures of CKD.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications